Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL(3)B

BACKGROUND: The high rate of mortality due to malaria and the worldwide distribution of parasite resistance to the commonly used antimalarial drugs chloroquine and pyrimethamine emphasize the urgent need for the development of new antimalarial drugs. An alternative approach to the long and uncertain...

Descripción completa

Detalles Bibliográficos
Autores principales: Reynolds, Jennifer M, El Bissati, Kamal, Brandenburg, Jens, Günzl, Arthur, Mamoun, Choukri Ben
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213633/
https://www.ncbi.nlm.nih.gov/pubmed/17956613
http://dx.doi.org/10.1186/1472-6904-7-13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213633/
https://www.ncbi.nlm.nih.gov/pubmed/17956613
http://dx.doi.org/10.1186/1472-6904-7-13

Ejemplares similares